Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CATB
  • CUSIP: N/A
  • Web: www.catabasis.com
Capitalization:
  • Market Cap: $51.48 million
  • Outstanding Shares: 22,481,000
Average Prices:
  • 50 Day Moving Avg: $2.09
  • 200 Day Moving Avg: $2.09
  • 52 Week Range: $1.08 - $5.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.96 per share
  • Price / Book: 2.39
Profitability:
  • EBITDA: ($31,270,000.00)
  • Return on Equity: -115.03%
  • Return on Assets: -83.58%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 3.73%
  • Quick Ratio: 3.73%
Misc:
  • Average Volume: 2.44 million shs.
  • Beta: 1.37
  • Short Ratio: 4.95
 

Frequently Asked Questions for Catabasis Pharmaceuticals (NASDAQ:CATB)

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.08. View Catabasis Pharmaceuticals' Earnings History.

When will Catabasis Pharmaceuticals make its next earnings announcement?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Catabasis Pharmaceuticals.

Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 1-year target prices for Catabasis Pharmaceuticals' stock. Their forecasts range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $5.42 in the next year. View Analyst Ratings for Catabasis Pharmaceuticals.

What are analysts saying about Catabasis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catabasis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (10/16/2017)
  • 2. Wedbush analysts commented, " With numerical improvements in all function-associated endpoints observed in Part B of the MoveDMD trial, we believe extended treatment with edasalonexent (CAT-1004) could result in a deepening of the response'a potential positive sign that could boost shares. We continue to look to Q2:17 for an interim look of the MoveDMD study at 24 weeks (Part C) as the next material catalyst. Q4/FY16 Financial Update: CATB reported no revenues and GAAP EPS (loss) of $(0.47)/$(2.22) vs. consensus of $(0.49)/$(2.25). CATB ended 2016 with ~$38.5 million in cash and cash equivalents and we project runway through Q1:18, in line with company guidance." (3/20/2017)

Are investors shorting Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 444,251 shares, a decrease of 37.6% from the August 31st total of 712,505 shares. Based on an average daily volume of 794,436 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.0% of the company's stock are sold short.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:

  • Kenneth M. Bate, Co-Chairman of the Board
  • Michael Jay Ross Ph. D., Director, Co-Chairman of the Board of Directors
  • Jill C. Milne Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Deirdre A. Cunnane J.D., Senior Vice President, General Counsel, Treasurer
  • Andrew Nichols Ph.D., Chief Scientific Officer
  • Joanne M. Donovan M.D. Ph.D., Chief Medical Officer
  • Edward Hibben, Chief Business Officer
  • Burt A. Adelman M.D., Independent Director
  • Jean M. George, Independent Director
  • Michael D. Kishbauch, Independent Director

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

How do I buy Catabasis Pharmaceuticals stock?

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $2.29.


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catabasis Pharmaceuticals (NASDAQ:CATB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.42 (136.54% upside)
Consensus Price Target History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Price Target History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Analysts' Ratings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Cowen and CompanyReiterated RatingMarket Perform$2.00N/AView Rating Details
10/5/2017CIBCReiterated RatingOutperform -> Outperform$4.00 -> $7.00N/AView Rating Details
10/5/2017Citigroup Inc.Set Price TargetHold$1.50 -> $3.50N/AView Rating Details
10/5/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$4.00 -> $7.00N/AView Rating Details
8/14/2017HC WainwrightBoost Price TargetBuy$8.00 -> $9.00MediumView Rating Details
6/21/2017WedbushReiterated RatingOutperform$4.00HighView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Earnings History by Quarter for Catabasis Pharmaceuticals (NASDAQ CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.33)N/AView Earnings Details
8/10/2017Q2 2017($0.40)($0.32)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.49)($0.47)ViewN/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/2/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
8/13/2015Q2 2015($0.70)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)
2017 EPS Consensus Estimate: ($1.46)
2018 EPS Consensus Estimate: ($1.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.35)($0.35)($0.35)
Q3 20172($0.35)($0.31)($0.33)
Q4 20172($0.36)($0.32)($0.34)
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.31)($0.31)($0.31)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Ownership Percentage: 40.70%
Institutional Ownership Percentage: 32.90%
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Trades by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catabasis Pharmaceuticals (NASDAQ:CATB)
Latest Headlines for Catabasis Pharmaceuticals (NASDAQ:CATB)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Downgrades Catabasis Pharmaceuticals, Inc. (CATB) to Hold
www.americanbankingnews.com - October 16 at 8:44 PM
americanbankingnews.com logoFY2019 EPS Estimates for Catabasis Pharmaceuticals, Inc. (CATB) Cut by Analyst
www.americanbankingnews.com - October 9 at 8:20 AM
americanbankingnews.com logoCowen and Company Reiterates "Market Perform" Rating for Catabasis Pharmaceuticals, Inc. (CATB)
www.americanbankingnews.com - October 6 at 1:44 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Given New $3.50 Price Target at Citigroup Inc.
www.americanbankingnews.com - October 5 at 4:20 PM
finance.yahoo.com logoCatabasis' DMD Candidate Slows Disease Progression, Stock Up
finance.yahoo.com - October 5 at 3:53 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Earns Outperform Rating from CIBC
www.americanbankingnews.com - October 5 at 1:33 PM
streetinsider.com logoCatabasis Pharma (CATB) Announces Positive Results from Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent
www.streetinsider.com - October 5 at 11:47 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals
finance.yahoo.com - October 5 at 11:47 AM
americanbankingnews.com logoOppenheimer Holdings, Inc. Raises Catabasis Pharmaceuticals, Inc. (CATB) Price Target to $7.00
www.americanbankingnews.com - October 5 at 11:42 AM
seekingalpha.com logoCatabasis Pharma's edasalonexent shows long-term treatment effect in mid-stage DMD study; shares ahead 59 ... - Seeking Alpha
seekingalpha.com - October 4 at 3:38 PM
benzinga.com logoMid-Morning Market Update: Markets Mostly Flat; PepsiCo Profit Tops Expectations - Benzinga
www.benzinga.com - October 4 at 3:38 PM
marketwatch.com logoCatabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment - MarketWatch
www.marketwatch.com - October 4 at 3:38 PM
finance.yahoo.com logoEvidence of Biotech Froth Continues to Mount
finance.yahoo.com - October 4 at 3:38 PM
247wallst.com logoWhy Catabasis Shares Are Surging
247wallst.com - October 4 at 12:32 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018
finance.yahoo.com - October 4 at 12:32 PM
finance.yahoo.com logoArmed with fresh trial data, Catabasis doubles down on Duchenne drug
finance.yahoo.com - October 4 at 12:32 PM
finance.yahoo.com logoCatabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment
finance.yahoo.com - October 4 at 12:32 PM
finance.yahoo.com logoCatabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
finance.yahoo.com - October 4 at 12:32 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals
finance.yahoo.com - October 3 at 4:50 PM
finance.yahoo.com logoCatella: European Residential Properties Show Large Potential for Appreciation
finance.yahoo.com - October 2 at 3:16 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society
finance.yahoo.com - October 2 at 3:16 PM
businesswire.com logoCatabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22 - Business Wire (press release)
www.businesswire.com - September 30 at 1:09 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Sees Significant Drop in Short Interest
www.americanbankingnews.com - September 30 at 3:26 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Receives Hold Rating from Citigroup Inc
www.americanbankingnews.com - September 29 at 6:00 PM
americanbankingnews.com logo Brokerages Expect Catabasis Pharmaceuticals, Inc. (CATB) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - September 28 at 12:34 AM
nasdaq.com logoHere's Why Sarepta Stock is Up More Than 60% So Far in 2017 - Nasdaq
www.nasdaq.com - September 25 at 7:51 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 23 at 9:10 AM
streetinsider.com logoCatabasis (CATB) to Present Results from Extension of MoveDMD Phase 2 Trial of Edasalonexent in Late Breaking Session of World Muscle Society
www.streetinsider.com - September 14 at 5:39 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
finance.yahoo.com - September 14 at 5:39 PM
finance.yahoo.com logoSarepta's Golodirsen Positive in DMD Study, Shares Soar
finance.yahoo.com - September 7 at 4:42 PM
finance.yahoo.com logoCatella AB's Comments on Nasdaq Stockholm's Trading Halt for the Company's Class A-Shares
finance.yahoo.com - August 29 at 5:18 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 9:06 AM
americanbankingnews.com logoWedbush Weighs in on Catabasis Pharmaceuticals, Inc.'s Q3 2017 Earnings (CATB)
www.americanbankingnews.com - August 16 at 7:22 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Catabasis Pharmaceuticals, Inc. Lifted by Analyst (CATB)
www.americanbankingnews.com - August 16 at 7:18 AM
americanbankingnews.com logoOppenheimer Holdings, Inc. Trims Catabasis Pharmaceuticals, Inc. (CATB) Target Price to $4.00
www.americanbankingnews.com - August 15 at 4:52 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Price Target Increased to $9.00 by Analysts at HC Wainwright
www.americanbankingnews.com - August 14 at 7:38 AM
seekingalpha.com logoCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 11 at 10:29 PM
finance.yahoo.com logoEdited Transcript of CATB earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 10:29 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 3:58 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress
finance.yahoo.com - August 10 at 6:08 PM
finance.yahoo.com logoCatabasis Pharmaceuticals posts 2Q loss
finance.yahoo.com - August 10 at 6:08 PM
businesswire.com logoCatabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference - Business Wire (press release)
www.businesswire.com - August 9 at 5:09 PM
finance.yahoo.com logoCatabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 5:09 PM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 4 at 8:52 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (CATB) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM
finance.yahoo.com logoCatabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10
finance.yahoo.com - July 27 at 4:21 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Yandex, Delta Air Lines, Target ... - Nasdaq
www.nasdaq.com - July 13 at 3:39 PM
americanbankingnews.com logo Analysts Expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 12 at 8:18 AM
americanbankingnews.com logoCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:46 AM
nasdaq.com logoSarepta Appoints Ex-Allergan Executive as CEO and President - Nasdaq
www.nasdaq.com - June 29 at 6:07 PM

Social

Chart

Catabasis Pharmaceuticals (CATB) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.